重组减毒活登革热疫苗(Dengvaxia)常规接种的长期安全性、公共卫生影响与成本效果:一项模型比较研究
八家独立建模组受世界卫生组织委托,模拟9岁儿童常规接种三剂Dengvaxia(覆盖率80%)后30年内的安全性、公共卫生影响与成本效果。在中高流行区(SP9≥50%)可减少登革热疾病负担6%–25%,高传播区(SP9≥70%)减少13%–25%;低传播区(SP9≤30%)模型预测住院可能大幅增加。疫苗价格有竞争力时,多数流行区具潜在成本效果。
要点
- 中高流行区(SP9≥50%)常规接种可减少登革热疾病负担6%–25%,高传播区(SP9≥70%)减少13%–25%。
- 低传播区(SP9≤30%)模型预测接种可能导致登革热住院大幅增加。
- 疫苗价格有竞争力时,多数流行区预测具潜在成本效果。
核心结论
- Dengvaxia有潜力减少中高登革热流行区的登革热疾病负担。
- 低暴露区的接种潜在风险以及当地成本与效益是将Dengvaxia纳入现有免疫规划的重要考量。
- 这些结果是世界卫生组织该疫苗全球政策的重要输入。
研究设计与样本
- 八家独立建模组受世界卫生组织委托开展模型比较研究。
- 默认接种策略为9岁儿童三剂次常规接种、覆盖率80%。
- 评估接种后30年内的感染、症状性登革热、住院登革热、死亡与成本效果。
- 病例定义依据III期试验选择。
主要发现
- 中高流行区(SP9≥50%)默认接种策略减少登革热疾病负担6%–25%(所有模拟:-3%–34%)。
- 高传播区(SP9≥70%)减少登革热疾病负担13%–25%(所有模拟:10%–34%)。
- 低传播区(SP9≤30%)模型预测接种可能导致登革热住院大幅增加。
- 降低疫苗覆盖率或增加补种活动显示,接种影响大致随接种人数线性变化。
- 中传播区(SP9=50%)针对较大年龄儿童接种可增加净效益。
临床怎么用
- 原文未据此给出推荐,仅指出低暴露区接种风险及当地成本效益是纳入免疫规划的重要考量。
局限性
- 结果基于疫苗作用与自然感染相似的假设,该假设与现有试验结果一致,但在缺乏额外数据时无法直接验证。
- 关于针对疾病与针对感染的保护水平以及疫苗诱导保护下降速率仍存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Large Phase III trials across Asia and Latin America have recently demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 mo following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. We here report predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine vaccination with Dengvaxia in a range of transmission settings, as characterised by seroprevalence levels among 9-y-olds (SP9). These predictions were conducted for the World Health Organization to inform their recommendations on optimal use of this vaccine. METHODS AND FINDINGS: The models adopted, with small variations, a parsimonious vaccine mode of action that was able to reproduce quantitative features of the observed trial data. The adopted mode of action assumed that vaccination, similarly to natural infection, induces transient, heterologous protection and, further, establishes a long-lasting immunogenic memory, which determines disease severity of subsequent infections. The default vaccination policy considered was routine vaccination of 9-y-old children in a three-dose schedule at 80% coverage. The outcomes examined were the impact of vaccination on infections, symptomatic dengue, hospitalised dengue, deaths, and cost-effectiveness over a 30-y postvaccination period. Case definitions were chosen in accordance with the Phase III trials. All models predicted that in settings with moderate to high dengue endemicity (SP9 ≥ 50%), the default vaccination policy would reduce the burden of dengue disease for the population by 6%-25% (all simulations: -3%-34%) and in high-transmission settings (SP9 ≥ 70%) by 13%-25% (all simulations: 10%- 34%). These endemicity levels are representative of the participating sites in both Phase III trials. In contrast, in settings with low transmission intensity (SP9 ≤ 30%), the models predicted that vaccination could lead to a substantial increase in hospitalisation because of dengue. Modelling reduced vaccine coverage or the addition of catch-up campaigns showed that the impact of vaccination scaled approximately linearly with the number of people vaccinated. In assessing the optimal age of vaccination, we found that targeting older children could increase the net benefit of vaccination in settings with moderate transmission intensity (SP9 = 50%). Overall, vaccination was predicted to be potentially cost-effective in most endemic settings if priced competitively. The results are based on the assumption that the vaccine acts similarly to natural infection. This assumption is consistent with the available trial results but cannot be directly validated in the absence of additional data. Furthermore, uncertainties remain regarding the level of protection provided against disease versus infection and the rate at which vaccine-induced protection declines. CONCLUSIONS: Dengvaxia has the potential to reduce the burden of dengue disease in areas of moderate to high dengue endemicity. However, the potential risks of vaccination in areas with limited exposure to dengue as well as the local costs and benefits of routine vaccination are important considerations for the inclusion of Dengvaxia into existing immunisation programmes. These results were important inputs into WHO global policy for use of this licensed dengue vaccine.
引用
- Flasche S, Jit M, Rodríguez-Barraquer I, et al. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Med. 2016. PMID: 27898668. doi:10.1371/journal.pmed.1002181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。